Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 19594734)

1.
2.

Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data.

Hall PS, Hamilton P, Hulme CT, Meads DM, Jones H, Newsham A, Marti J, Smith AF, Mason H, Velikova G, Ashley L, Wright P.

Br J Cancer. 2015 Mar 3;112(5):948-56. doi: 10.1038/bjc.2014.644. Epub 2015 Jan 20.

PMID:
25602964
3.

Prostate cancer screening: going beyond the clinical evidence.

Krahn M.

CMAJ. 2014 Nov 4;186(16):1201-2. doi: 10.1503/cmaj.141252. Epub 2014 Oct 27. No abstract available.

PMID:
25349002
4.

Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.

Dragomir A, Cury FL, Aprikian AG.

CMAJ Open. 2014 Apr 24;2(2):E60-8. doi: 10.9778/cmajo.20130037. eCollection 2014 Apr.

5.

Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study.

de Oliveira C, Bremner KE, Pataky R, Gunraj N, Chan K, Peacock S, Krahn MD.

CMAJ Open. 2013 Jan 16;1(1):E1-8. doi: 10.9778/cmajo.20120013. eCollection 2013 Jan.

6.

Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.

Krahn MD, Bremner KE, Luo J, Alibhai SM.

Curr Oncol. 2014 Jun;21(3):e457-65. doi: 10.3747/co.21.1865.

7.

Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.

Dragomir A, Dinea D, Vanhuyse M, Cury FL, Aprikian AG.

BMC Health Serv Res. 2014 Jun 13;14:252. doi: 10.1186/1472-6963-14-252.

8.

Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.

Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, Pickles T, Tyldesley S, Peacock S.

Int J Cancer. 2014 Aug 15;135(4):939-47. doi: 10.1002/ijc.28732. Epub 2014 Feb 4.

9.

Direct cost for initial management of prostate cancer: a systematic review.

Sanyal C, Aprikian AG, Chevalier S, Cury FL, Dragomir A.

Curr Oncol. 2013 Dec;20(6):e522-31. doi: 10.3747/co.20.1630.

10.

Analysis of urological procedures in men who died from prostate cancer using a population-based approach.

Babaian K, Truong M, Cetnar J, Cross DS, Shi F, Ritter MA, Jarrard DF.

BJU Int. 2013 Mar;111(3 Pt B):E65-70. doi: 10.1111/j.1464-410X.2012.11517.x. Epub 2012 Nov 6.

11.

Direct cost associated with acquired brain injury in Ontario.

Chen A, Bushmeneva K, Zagorski B, Colantonio A, Parsons D, Wodchis WP.

BMC Neurol. 2012 Aug 17;12:76. doi: 10.1186/1471-2377-12-76.

12.

Techniques for estimating health care costs with censored data: an overview for the health services researcher.

Wijeysundera HC, Wang X, Tomlinson G, Ko DT, Krahn MD.

Clinicoecon Outcomes Res. 2012;4:145-55. doi: 10.2147/CEOR.S31552. Epub 2012 Jun 1.

13.

Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.

Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP.

Cancer. 2012 Jul 15;118(14):3512-8. doi: 10.1002/cncr.26688. Epub 2011 Dec 16.

14.

Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.

Engel-Nitz NM, Alemayehu B, Parry D, Nathan F.

Cancer Manag Res. 2011;3:233-45. doi: 10.2147/CMR.S21033. Epub 2011 Jul 4.

15.

End-of-life care for lung cancer patients in the United States and Ontario.

Warren JL, Barbera L, Bremner KE, Yabroff KR, Hoch JS, Barrett MJ, Luo J, Krahn MD.

J Natl Cancer Inst. 2011 Jun 8;103(11):853-62. doi: 10.1093/jnci/djr145. Epub 2011 May 18.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk